Stock listing

TWSE:6550 Polaris Group (北極星藥業-KY) 股價

Follow Polaris Group into a list and get an email when it puts out news.

Share price · TWSE:6550

$10.85 TWD -2.00 (-15.6%)

Close on Nov 20, 2026

Past year -80.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$10.85 – $11.85 TWDNov 20, 2026
Volume
834,010 sharesNov 20, 2026
Market cap
$5.04B TWDAt the close on Nov 20, 2026 · price × 464.8M shares outstanding
52-week range
$10.85 – $69.20 TWDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$7.90M TWDMedian day 411,950 shares · 7 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Polaris Group logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TWSE:6550 · TWD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$10.85-2.00-15.6%$11.85$11.85$10.85834,010
$12.85-0.20-1.5%$13.20$13.35$12.70368,788
$13.05-0.10-0.8%$13.10$13.60$12.90468,375
$13.15-0.60-4.4%$13.50$13.80$13.15337,982
$13.75+0.25+1.9%$13.40$13.80$13.40504,887
$13.50-0.25-1.8%$13.70$13.80$13.40288,052
$13.75-0.35-2.5%$14.20$14.20$13.60272,155
$14.10+0.15+1.1%$14.20$14.40$13.80482,923
$13.95+0.25+1.8%$13.80$15.00$13.80636,107
$13.70-0.60-4.2%$13.10$13.95$13.10618,385
$14.30-0.50-3.4%$14.70$15.00$14.30418,772
$14.800.000.0%$14.90$14.90$14.30357,888
$14.80-0.25-1.7%$14.90$15.05$14.60511,332
$15.05+0.30+2.0%$14.60$15.25$14.60276,755
$14.75-0.45-3.0%$15.45$15.45$14.65396,948
$15.200.000.0%$15.20$15.25$15.15125,409
$15.20-0.05-0.3%$15.35$15.45$15.20186,826
$15.25-0.20-1.3%$15.45$15.45$15.25196,101
$15.450.000.0%$15.45$15.45$15.450
$15.45-0.25-1.6%$15.90$15.90$15.45242,718
$15.70+0.20+1.3%$15.65$15.90$15.55223,136
$15.50-0.05-0.3%$15.35$15.55$15.30405,128
$15.55-0.55-3.4%$16.15$16.15$15.50351,637
$16.10+0.20+1.3%$15.95$16.30$15.95239,284
$15.90-0.20-1.2%$16.10$16.30$15.80448,830
$16.10+0.20+1.3%$16.05$16.30$16.05333,233
$15.90-0.45-2.8%$16.35$16.40$15.75500,237
$16.35-0.35-2.1%$16.90$16.95$16.35436,206
$16.70+0.65+4.0%$16.15$16.90$16.15750,436
$16.050.000.0%$16.10$16.60$16.00542,662
$16.05-0.15-0.9%$16.20$16.45$16.05432,776
$16.20-0.55-3.3%$16.75$16.80$16.20900,248
$16.75-0.75-4.3%$17.50$17.50$16.751,169,236
$17.50-0.35-2.0%$17.80$17.80$17.40489,604
$17.85+0.45+2.6%$17.25$17.95$16.901,532,271
$17.40-1.695-8.9%$18.25$18.35$17.201,514,855
$19.100.000.0%$19.10$19.10$19.100
$19.100.000.0%$19.10$19.10$19.100
$19.100.000.0%$19.10$19.10$19.100
$19.100.000.0%$19.10$19.10$19.100
$19.100.000.0%$19.10$19.10$19.100
$19.100.000.0%$19.10$19.10$19.100
$19.10+0.038+0.2%$19.25$19.35$19.08536,281
$19.060.000.0%$19.06$19.44$19.06530,289
$19.06-0.135-0.7%$19.23$19.23$19.02954,392
$19.19-0.443-2.3%$19.54$19.54$19.19599,281
$19.63-0.096-0.5%$19.83$19.83$19.35187,058
$19.73+0.192+1.0%$19.25$19.83$19.23722,557
$19.54-0.289-1.5%$19.73$19.92$19.23544,372
$19.83-0.096-0.5%$20.12$20.12$19.63216,202
$19.92+0.096+0.5%$19.83$20.02$19.63221,060
$19.83-0.577-2.8%$20.60$20.60$19.83269,860
$20.40-0.192-0.9%$20.21$20.60$20.21146,923
$20.600.000.0%$20.40$20.79$19.83402,362
$20.60-0.962-4.5%$21.56$21.66$20.21583,620
$21.56-0.289-1.3%$22.14$22.33$21.56309,311
$21.85-0.385-1.7%$22.71$23.68$21.75543,053
$22.23+1.059+5.0%$21.37$22.71$21.37552,867
$21.17-1.155-5.2%$22.04$22.14$21.08536,865
$22.33-1.251-5.3%$24.93$25.02$21.941,627,118
$23.58+2.117+9.9%$23.58$23.58$23.10380,959
$21.46+1.925+9.9%$19.83$21.46$19.83530,380

Splits

1 split · TWSE:6550 · every price before a split is adjusted for it

DayRatioWhat
40-for-77Consolidation
Ticker
TWSE:6550
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
TWSE
Currency
TWD

What changed lately

Latest news

All Polaris Group news

Polaris Group on 6ix

Sector
Health care
Industry
Biotechnology
News releases
1 in the last 12 months · 10 in all · newest Sep 28, 2026 · oldest 2022
Decks
1 deck · latest May 4, 2022

Valuation

EV/sales 75.1× against a median of 88.1×: 5th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$5.10B TWD
P/E
Loss
EV/sales
75.1×
EV/EBITDA
Negative EBITDA
Price/book
1.1×
Gross margin
−618.2%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.5×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Polaris Group · TWSE:6550US$153.0MUS$154.8Mn/a75.1×n/a1.1×n/a0.5×n/a
ImmuneOncia Therapeutics Inc. · KRX:424870US$159.0MUS$89.79Mn/an/an/a2.1×n/a0.0×n/a
Jiangsu Recbio Technology Co., Ltd. Class H · HKEX:2179US$157.3MUS$230.2Mn/a124×n/a2.1×n/a1.4×n/a
BioVersys AG · SIX:BIOVUS$154.1MUS$97.45Mn/a102×n/a2.9×n/a0.5×n/a
InflaRx N.V. · NASDAQ:IFRXUS$153.3MUS$135.7Mn/a4,215×n/a19.5×n/a0.0×1.61
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H · HKEX:1541US$152.0MUS$64.40Mn/a2.9×n/a1.6×−141.7%0.6×n/a
Saniona AB · OMXSTO:SANIONUS$151.6MUS$104.0M8.4×2.5×5.2×2.8×43.2%0.0×n/a
Palisade Bio, Inc. · NASDAQ:PALIUS$150.6MUS$36.96Mn/a73.9×n/a1.3×n/a0.0×1.41
Eledon Pharmaceuticals, Inc. · NASDAQ:ELDNUS$150.3MUS$80.67Mn/an/an/a4.9×n/a0.0×1.95
Veraxa Biotech AG · NASDAQ:VRXAUS$147.1MUS$145.1Mn/a5,202×n/an/an/an/a1.11
ProQR Therapeutics N.V. · NASDAQ:PRQRUS$146.8MUS$49.73Mn/a2.2×n/a2.0×−210.7%0.2×1.73
Median of the othersUS$151.8MUS$93.62M8.4×88.1×5.2×2.1×−141.7%0.0×1.61

Team and board

Officers

OfficerRole
Samuel ChenChairman & Chief Executive Officer
Amanda JohnstonSenior Vice President, Clinical Affairs
Chris HuxsollSenior Vice President, Operations
John BomalaskiExecutive Vice President, Medical Affairs

Board

DirectorRole
Samuel ChenChairman & Chief Executive Officer

Events

QuarterResultsShare move
Q1 2023May 11, 2023 · After close+1.2%
Q4 2022Mar 16, 2023 · After close+2.8%
Q3 2022Nov 13, 2022 · After close−2.5%
Q2 2022Aug 21, 2022 · After close+3.9%

Open Events

Decks

DeckKindSlidesDate
IPO Roadshow (May 2022)IPO roadshow34 slidesMay 4, 2022

Open Decks

Financials

Annual, in TWD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue40.6M107.0M7.48M6.44M15.0M9.41M
Cost of revenue310.9M183.9M145.4M148.3M165.7M140.2M138.3M110.5M113.8M128.1M
Gross profit-270.3M-76.9M-137.9M-141.9M-150.6M-130.8M-138.3M-110.5M-113.8M-128.1M
Research and development2.16B2.19B1.54B924.0M554.3M545.2M633.1M785.9M615.9M697.8M
Selling, general and administrative346.1M330.5M307.3M235.0M179.7M135.3M162.1M
Operating income-2.88B-2.63B-1.85B-1.16B-731.9M-678.0M-795.2M-1.01B-843.7M-948.2M
Depreciation and amortization376.4M315.1M135.4M143.7M154.1M133.3M138.3M110.5M113.8M128.1M
EBITDA-2.50B-2.32B-1.71B-1.01B-577.8M-544.7M-656.9M-903.2M-729.9M-820.0M
Interest expense99.4M57.1M32.6M11.1M14.7M5.16M35.5M44.9M55.6M50.3M
Income before tax-3.94B-2.55B-1.56B-1.14B-730.5M-654.5M-828.9M-1.03B-897.4M-980.3M
Income tax390.0K5.21M15.6M5.53M777.0K48.0K820.0K47.0K1.08M2.16M
Net income-3.95B-2.50B-1.58B-1.15B-740.5M-660.2M-829.8M-1.03B-898.5M-982.5M
Earnings per share, basic-9.87-6.45-4.09-3.03-2.10-1.95-4.75-6.89-6.94-7.98

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents1.83B1.95B3.62B7.23B5.88B152.2M2.61B394.9M706.8M357.8M
Short-term investments913.0M1.18B1.33B156.0M446.3M1.70B9.87M
Receivables34.9M24.5M25.1M521.0K5.35M8.15M312.0K14.0K2.00K36.0K
Inventory121.9M67.4M36.4M0
Current assets3.02B3.33B5.11B7.54B6.35B1.88B2.64B428.0M731.3M373.9M
Goodwill755.4M2.07B
Total assets8.17B9.09B9.10B9.22B7.82B3.36B4.11B1.98B2.22B1.97B
Accounts payable9.12M2.33M2.14M521.0K
Current liabilities585.9M468.9M959.4M250.8M436.8M278.0M236.1M1.09B465.9M1.01B
Long-term debt2.09B1.62B353.0M30.8M117.3M126.2M202.3M
Total debt2.35B1.88B1.20B382.6M436.8M325.6M276.1M1.03B1.01B1.52B
Total liabilities2.87B2.32B1.46B545.2M608.2M480.9M496.6M1.34B1.22B1.73B
Shareholders' equity5.30B6.70B7.37B8.67B7.21B2.88B3.61B640.5M1.00B207.3M
Shares outstanding399.6M388.2M386.0M380.2M353.0M338.9M174.8M149.8M129.4M123.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-2.39B-2.03B-1.26B-1.03B-539.3M-585.7M-747.8M-778.7M-708.1M-782.5M
Capital spending-795.3M-1.66B-333.2M-69.6M-204.3M-51.7M-50.2M-43.2M-20.7M-305.1M
Free cash flow-3.19B-3.69B-1.59B-1.10B-743.6M-637.4M-798.0M-821.9M-728.8M-1.09B
Cash from investing-659.7M-1.63B-3.24B199.7M1.02B-1.79B-42.5M-58.7M-19.2M-268.5M
Cash from financing2.96B1.85B919.2M1.48B5.35B1.18M3.08B642.9M1.19B450.1M
Change in cash-115.8M-1.67B-3.61B1.35B5.73B-2.46B2.21B-311.9M349.0M-600.9M

Open Financials

Cap table

Built by 6ix from Polaris Group’s releases

Common shares
464,846,344
Fully diluted
464,846,344

Fully diluted

LineShares
Common shares464,846,344

Share count over time

CountShares
Nov 22, 2026464,846,344

Open Cap table

Shareholders

Register

HolderSharesOf the companyAs of
Digital Capital Inc.214M45.9%Oct 31, 2026
Mai Investment Co.,Ltd21.1M4.5%Oct 31, 2026
陳賢哲2.57M0.55%Oct 31, 2026
蔡高忠00.00%Oct 31, 2026
趙應誠00.00%Oct 31, 2026
張義芳00.00%Oct 31, 2026
張志剛00.00%Oct 31, 2026
沈意潔00.00%Oct 31, 2026
陳靜慧00.00%Oct 31, 2026
狄士傑00.00%Oct 31, 2026
All 14 holders
HolderSharesOf the companyAs of
John Bomalaski00.00%Oct 31, 2026
魏少筠00.00%Oct 31, 2026
周宏杰00.00%Oct 31, 2026
Digital Capital Inc.Nov 22, 2026

Funds

HolderSharesValueAs of
Vanguard Total International Stock Index Fund4.17MUS$1.39MJul 31, 2026
Vanguard Emerging Markets Stock Index Fund3.47MUS$1.16MJul 31, 2026
iShares Core MSCI Emerging Markets ETF2.07MUS$901KMay 31, 2026
Vanguard Ftse All-World Ex-Us Small-Cap Index Fund1.29MUS$430KJul 31, 2026
State Street(R) SPDR(R) Portfolio Emerging Markets ETF269KUS$115KJun 30, 2026
State Street(R) SPDR(R) S&P(R) Emerging Markets Small Cap ETF186KUS$79,321Jun 30, 2026
Vanguard Total World Stock Index Fund180KUS$59,981Jul 31, 2026
The Emerging Markets Small Cap Series143KUS$47,784Jul 31, 2026
World ex U.S. Core Equity Portfolio103KUS$34,418Jul 31, 2026
Emerging Markets Social Core Equity Portfolio91,000US$30,408Jul 31, 2026
All 13 holders
HolderSharesValueAs of
Vanguard ESG International Stock ETF56,415US$24,533May 31, 2026
Emerging Markets ex China Core Equity Portfolio56,000US$18,713Jul 31, 2026
Parametric Emerging Markets Fund27,979US$9,349Jul 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Amanda JohnstonSenior Vice President, Clinical Affairs · Since at least Nov 5, 2026
Chris HuxsollSenior Vice President, Operations · Since at least Nov 5, 2026
John BomalaskiExecutive Vice President, Medical Affairs · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Polaris Group.